Supernus Pharmaceuticals, Inc. (SUPN)
Develops medications treating brain and nerve disorders like ADHD, Parkinson's, and epilepsy.
$47.73+0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+34.4%
The outlook
SUPN trades at $47.73, positioned roughly midway in its 52-week range. Analyst consensus is strongly bullish with an average price target around 33% above current levels. The stock shows mixed momentum against its moving averages, though the overall data lean is constructive.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 6 analysts
Price trendMixed vs its moving averages
52-week range55% of the way from its 52-week low to high
Price targetAvg target +33% vs current price
Analyst price target
~12-month · 6 analysts$63.50average target+33.0% vs now
Now $47.73
Low $55.00High $67.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.77B
52-wk high
$59.68
52-wk low
$32.83
50-day avg
$46.62
200-day avg
$49.07
Trailing P/E
—